Clinical Trial

Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy

Study acronym: Sema-RMA
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 15, 2024 (before its estimated March 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this double-blinded, placebo-controlled, randomized, crossover study is to examine the effect of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), on renal hemodynamics and function in patients with type 2 diabetes mellitus (T2DM) and moderate chronic kidney disease (CKD). The study will determine the effects of semaglutide on: * Renal arterial blood flow, regional renal perfusion, and oxygenation * Activity of the renin-angiotensin-aldosterone system (RAAS) * The glomerular filtration rate (GFR) * Sodium excretion in urine * Blood pressure and heart rate
Trial Details
NCT Number NCT06555146
Lead Sponsor Bispebjerg Hospital
Conditions Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Enrollment 15 participants
Start Date 2024-08
Primary Completion 2025-03 (estimated)
Study Completion 2025-03 (estimated)
Updated on ClinicalTrials.gov 2024-08-15